Qiliqiangxin Modulates the Gut Microbiota and NLRP3 Inflammasome to Protect Against Ventricular Remodeling in Heart Failure

Aims: Pathological left ventricular (LV) remodeling induced by multiple causes often triggers fatal cardiac dysfunction, heart failure (HF), and even cardiac death. This study is aimed to investigate whether qiliqiangxin (QL) could improve LV remodeling and protect against HF via modulating gut micr...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingdong Lu (Author), Mi Xiang (Author), Laiyun Xin (Author), Yang Zhang (Author), Yuling Wang (Author), Zihuan Shen (Author), Li Li (Author), Xiangning Cui (Author)
Format: Book
Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_7b2a081c42e341579f6019f78833a2a5
042 |a dc 
100 1 0 |a Yingdong Lu  |e author 
700 1 0 |a Mi Xiang  |e author 
700 1 0 |a Laiyun Xin  |e author 
700 1 0 |a Laiyun Xin  |e author 
700 1 0 |a Yang Zhang  |e author 
700 1 0 |a Yang Zhang  |e author 
700 1 0 |a Yuling Wang  |e author 
700 1 0 |a Zihuan Shen  |e author 
700 1 0 |a Li Li  |e author 
700 1 0 |a Xiangning Cui  |e author 
245 0 0 |a Qiliqiangxin Modulates the Gut Microbiota and NLRP3 Inflammasome to Protect Against Ventricular Remodeling in Heart Failure 
260 |b Frontiers Media S.A.,   |c 2022-06-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2022.905424 
520 |a Aims: Pathological left ventricular (LV) remodeling induced by multiple causes often triggers fatal cardiac dysfunction, heart failure (HF), and even cardiac death. This study is aimed to investigate whether qiliqiangxin (QL) could improve LV remodeling and protect against HF via modulating gut microbiota and inhibiting nod-like receptor pyrin domain 3 (NLRP3) inflammasome activation.Methods: Rats were respectively treated with QL (100 mg/kg/day) or valsartan (1.6 mg/kg/day) by oral gavage after transverse aortic constriction or sham surgery for 13 weeks. Cardiac functions and myocardial fibrosis were assessed. In addition, gut microbial composition was assessed by 16S rDNA sequencing. Furthermore, rats' hearts were harvested for histopathological and molecular analyses including immunohistochemistry, immunofluorescence, terminal-deoxynucleotidyl transferase-mediated 2'-deoxyuridine 5'-triphosphated nick end labeling, and Western blot.Key findings: QL treatment preserved cardiac functions including LV ejection fractions and fractional shortening and markedly improved the LV remodeling. Moreover, HF was related to the gut microbial community reorganization like a reduction in Lactobacillus, while QL reversed it. Additionally, the protein expression levels like IL-1β, TNF-α, NF-κB, and NLRP3 were decreased in the QL treatment group compared to the model one.Conclusion: QL ameliorates ventricular remodeling to some extent in rats with HF by modulating the gut microbiota and NLRP3 inflammasome, which indicates the potential therapeutic effects of QL on those who suffer from HF. 
546 |a EN 
690 |a gut microbiota 
690 |a NLRP3 inflammasome 
690 |a qiliqiangxin 
690 |a heart failure 
690 |a ventricular remodeling 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 13 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2022.905424/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/7b2a081c42e341579f6019f78833a2a5  |z Connect to this object online.